Introduction: Recombinant α1-microglobulin (A1M) is a proposed radioprotector during 177Lu-octreotate treatment of neuroendocrine tumors. Treatment with 177Lu-octreotate is currently limited by bone marrow and renal toxicity. Co-administration of 177Lu-octreotate and A1M could result in a more effec...
Purpose: 177Lu-octreotate is used for therapy of somatostatin receptor expressing neuroendocrine tumors. Despite being highly effective in animal models, 177Lu-octreotate-based therapies have shown low cure rates in clinical studies. A better understanding of the molecular mechanisms underlying resp...
The radiolabelled somatostatin analogue 177Lu-octreotate is a promising treatment option for malignant neuroendocrine tumors that overexpress somatostatin receptors. The human small intestine neuroendocrine tumor cell line GOT1 and Medullary thyroid carcinoma model GOT2 have shown promising treatmen...
The radiolabelled somatostatin analogue 177Lu-octreotate is a promising treatment option for malignant neuroendocrine tumors that overexpress somatostatin receptors. The human small intestine neuroendocrine tumor cell line GOT1 and Medullary thyroid carcinoma model GOT2 have shown promising treatmen...
